ArticleNPJ breast cancer2020
Association of germline variation with the survival of women with
Open access · goldAbstract read
In one paragraph
Article in NPJ breast cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Clinical characteristics of patients with Breast and / or Ovarian Cancer with mutations in the BRCA1 and BRCA2 genes in Córdoba, ArgentinaRevista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2022Article
- Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.Cancer research · 2022Article
- Characterization of SynonymousFrontiers in oncology · 2021Article
- Association of germline variation with the survival of women withNPJ breast cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 20 institutions in 14 countries.
Taru A MuranenUniversity of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-5895-1808
Sofia KhanUniversity of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland.
Rainer FagerholmUniversity of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland.
Kristiina AittomäkiUniversity of Helsinki, Department of Clinical Genetics, Helsinki University Hospital, Helsinki, Finland.
Julie M CunninghamMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN USA.ORCID 0000-0002-8159-3025
Joe DennisUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.ORCID 0000-0003-4591-1214
Goska LeslieUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.ORCID 0000-0001-5756-6222
Lesley McGuffogUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
Michael T ParsonsQIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD Australia.ORCID 0000-0003-3242-8477
Jacques SimardCHU de Quebec Research Center, Genomics Center, Québec City, QC Canada.ORCID 0000-0001-6906-3390
Susan SlagerMayo Clinic, Department of Health Sciences Research, Rochester, MN USA.
Penny SoucyCHU de Quebec Research Center, Genomics Center, Québec City, QC Canada.
Douglas F EastonUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.ORCID 0000-0003-2444-3247
Marc TischkowitzMcGill University, Program in Cancer Genetics, Departments of Human Genetics and Oncology, Montréal, QC Canada.
Amanda B SpurdleQIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD Australia.ORCID 0000-0003-1337-7897
kConFab Investigators
Rita K SchmutzlerFaculty of Medicine and University Hospital Cologne, University of Cologne, Center for Hereditary Breast and Ovarian Cancer, Cologne, Germany.
Barbara WappenschmidtFaculty of Medicine and University Hospital Cologne, University of Cologne, Center for Hereditary Breast and Ovarian Cancer, Cologne, Germany.
Eric HahnenFaculty of Medicine and University Hospital Cologne, University of Cologne, Center for Hereditary Breast and Ovarian Cancer, Cologne, Germany.
Maartje J HooningErasmus MC Cancer Institute, Department of Medical Oncology, Family Cancer Clinic, Rotterdam, The Netherlands.
HEBON Investigators
Christian F SingerMedical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, Austria.
Gabriel WagnerMedical University of Vienna, Dept of OB/GYN and Comprehensive Cancer Center, Vienna, Austria.
Mads ThomassenOdense University Hospital, Department of Clinical Genetics, Odence C, Denmark.
Inge Sokilde PedersenAalborg University Hospital, Molecular Diagnostics, Aalborg, Denmark.ORCID 0000-0002-9902-8040
Susan M DomchekPerelman School of Medicine at the University of Pennsylvania, Department of Medicine, Abramson Cancer Center, Philadelphia, PA USA.
Katherine L NathansonPerelman School of Medicine at the University of Pennsylvania, Department of Medicine, Abramson Cancer Center, Philadelphia, PA USA.ORCID 0000-0002-6740-0901
Conxi LazaroICO-IDIBELL (Bellvitge Biomedical Research Institute, Catalan Institute of Oncology), CIBERONC, Molecular Diagnostic Unit, Hereditary Cancer Program, Barcelona, Spain.ORCID 0000-0002-7198-5906
Caroline Maria RossingRigshospitalet, Copenhagen University Hospital, Center for Genomic Medicine, Copenhagen, Denmark.
Irene L AndrulisLunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON Canada.ORCID 0000-0002-4226-6435
Manuel R TeixeiraPortuguese Oncology Institute, Department of Genetics, Porto, Portugal.ORCID 0000-0002-4896-5982
Paul JamesPeter MacCallum Cancer Center, Parkville Familial Cancer Centre, Melbourne, VIC Australia.ORCID 0000-0002-4361-4657
Judy GarberDana-Farber Cancer Institute, Cancer Risk and Prevention Clinic, Boston, MA USA.
Jeffrey N WeitzelCity of Hope, Clinical Cancer Genomics, Duarte, CA USA.ORCID 0000-0001-6714-092X
SWE-BRCA Investigators
Anna JakubowskaPomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland.ORCID 0000-0002-5650-0501
Drakoulis YannoukakosNational Centre for Scientific Research 'Demokritos', Molecular Diagnostics Laboratory, INRASTES, Athens, Greece.ORCID 0000-0001-7509-3510
Esther M JohnStanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA USA.
Melissa C SoutheyMonash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, VIC Australia.
Marjanka K SchmidtThe Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands.ORCID 0000-0002-2228-429X
Antonis C AntoniouUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, QLD Australia.
Carl BlomqvistUniversity of Helsinki, Department of Oncology, Helsinki University Hospital, Helsinki, Finland.
Heli NevanlinnaUniversity of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-0916-2976
University of Helsinki · FIUniversity of Cambridge · GBUniversity of Cologne · DEQIMR Berghofer Medical Research Institute · AUThe University of Melbourne · AUAalborg University Hospital · DKCentre hospitalier universitaire de Québec · CAComprehensive Cancer Center Vienna · ATNational Centre of Scientific Research "Demokritos" · GROdense University Hospital · DKUniversidade do Porto · PTÅbo Akademi University · FICopenhagen University Hospital · DKDana-Farber Cancer Institute · USInstitut d'Investigació Biomédica de Bellvitge · ESMayo Clinic in Arizona · USMayo Clinic in Florida · USMount Sinai Hospital · CAPeter MacCallum Cancer Centre · AUStanford University · US
Funding
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6MCancer Research UK 11174Cancer Research UK 20861Cancer Research UK 23382NCI NIH HHS U19 CA148065NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008I
Abstract
Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline pathogenic variants in
Indexed as
Breast cancerCancer geneticsGenome-wide association studies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.